fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-02-03 III Result NeuroSearch (Denmark)   Huntexil® (ACR16 - dopaminergic stabiliser -pridopidine) Huntington's disease Europe See details
2010-02-01 IIa Result Synosia Therapeutics (Switzerland)   SYN-115 (adenosine 2a (A2a) receptor antagonist) It is being developed by Synosia as a potential add-on therapy to a stable dose of levodopa or as a monotherapy. Rights to SYN-115 were obtained from Roche in 2007 for development in selected indications of the central nervous system. Parkinson’s Disease   See details
2010-01-28 I Launch   Bayer Innovation personalized vaccine from tobacco plants ( This patient-specific vaccine uses Bayer's magnICON® technology for the production of plant-made pharmaceutical proteins. It is produced in the pilot plant operated by the Bayer-subsidiary Icon Genetics in Halle, Germany (See http://www.biopharmaceutiques.com/en/article/79_1500.html). non-Hodgkin’s lymphoma USA See details
2010-01-25 II-III Launch BiogenIdec (USA) Swedish Orphan Biovitrum (Sweden)   long acting recombinant factor IXFc fusion protein (rFIXFc) hemophilia B USA See details
2010-01-25 II Result   Bayer Schering Pharma (Germany) BAY79-4980 (long-acting recombinant factor VIII) hemophilia   See details
2010-01-21 I Launch 4SC (Germany)   4SC-203 (multi-target kinase inhibitor with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R). This compound was co-developed with ProQinase GmbH, Freiburg, Germany (www.proqinase.com). cancer   See details
2010-01-21 III Launch Agennix (Germany)   talactoferrin non-small cell lung cancer International See details
2010-01-21 IIa Launch BTG (UK)   Pleneva® (formerly BGC20-0134) multiple sclerosis   See details
2010-01-20 III Result   Novartis (Switzerland) FTY720 (fingolimod - sphingosine 1-phosphate (S1P) receptor modulator) multiple sclerosis   See details
2010-01-19 IIb Launch Oramed Pharmaceuticals (Israel)   oral insulin capsule ORMD-0801 type 2 diabetes South Africa See details
2010-01-19 I Result Biotie Therapies (Finland)   BTT-1023 (VAP-1 Antibody) rheumatoid arthritis   See details
2010-01-13 I Launch Novo Nordisk (Denmark)   NN9924 (long-acting oral GLP-1 analogue) type 2 diabetes UK See details
2010-01-13 II Launch AVIR Green Hills Biotechnology (Austria)   intranasal, seasonal H1N1 influenza vaccine deltaFLU. influenza Austria See details
2010-01-12 IIa Launch Cytheris (France)   CYT107 (recombinant human Interleukin-7) treatment of chronically infected HIV patients who fail to achieve optimal immune reconstitution under HAART therapy USA and Canada See details
2010-01-12 II Launch 4SC (Germany)   4SC-201 (reminostat - oral pan-histone deacetylase (HDAC) inhibitor) Hodgkin's lymphoma Poland, Romania and Czech Republic See details
[<<]      «      3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13      »      [57]